[Retracted] Second-Generation Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response: A Systematic Review and a Meta-Analysis

Table 1

Characteristics of studies included in the meta-analysis.

Study	Sample size ()	Female (%)	Age (years)	Sokal H/I/L (%)	Previous therapy	Type of TKI therapy	Molecular response before 2G-TKI discontinuation	Definition of molecular relapse	2G-TKI median duration (month)	TFR at 12 months (%)	TFR at 24 months (%)	National or international	Median follow-up (months)	NOS score	Quality of study
Rea D 2017 [29]	60	63.3	60	15/27/53	IFN/Ima	Dasa, Nilo	MR4.5	Loss of MMR	39	63.33	60.0	National	47	4
Ross DM 2018 [30]	190	49.5	55	15/26/33	No	Nilo	MR4.5	Loss of MMR	31	51.6	48.9	International	19	7	H
Okada M 2018 [28]	63	35	59	14/14/65	Ima	Dasa	MR4.0	Loss of MR4.0	17	48.0	44.0	National	44	6
Mahon FX 2018 [27]	126	56	56	NR	Ima	Nilo	MR4.5	Loss of MMR	53	58.0	53.0	International	NR	7	H
Takahashi N 2018 [31]	78	42.3	55.5	21/22/56	IFN/Ima	Nilo	MR4.5	Loss of MR4.5	7.7	67.9	62.8	National	35.4	7	H

Sokal score H/I/L: high, intermediate, low; IFN: interferon; NR: not reported; H: high-quality study.